Agree. Although the cash leftover won't be huge - so they're better off pursuing partnerships to stretch the capital. e.g. NASA with the Spaceflight associated neuro-ocular syndrome (SANS).
Pertinently, Sinclair is working with UK Royal Centre for Defence Medicine on defining accurate biomarkers for mild Traumatic Brain Injury - important step prior to trialing a GLP-1 agonist to ascertain its effect. https://www.birmingham.ac.uk/staff/profiles/metabolism-systems/sinclair-alexandra.aspx
Ann: Notice of Investor Call and Presentation, page-139
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.335M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 532 | 7.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.5¢ | 8695 | 1 |
View Market Depth
| Last trade - 16.12pm 09/08/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable